Facts About Cancer

More than 80% of all cancer patients die from metastasis, not the actual primary tumour. Metastasis is therefore the real killer.

Cancer is complex, heterogeneous and dynamic. Cancer invades and robs; its innate ability to evade standard detection and their evolutionary nature makes treatment fraught with uncertainty.

For the patient, a cancer treatment journey drains physically, emotionally, mentally and financially. For the oncologist, it may mean questions of possible overtreatment and having to subject patients to frequent, painful biopsies. Over the course of treatment, the cancer can evolve and become resistant.

Therefore the ability to precisely detect these changes facilitates timely diagnosis and staging of the disease; this ability is critical for precise, tailored treatment and proactive monitoring. This is where Circulating Tumour Cells (CTCs) become critically relevant.

What Are CTCs

Circulating Tumour Cells (CTCs) are extremely rare cells that have detached from solid tumours, travel in the bloodstream and can cause the cancer to spread.

They are considered the seeds in metastasis and can be a clear indication of disease progression.

A blood test, or liquid biopsy that can detect and profile these CTCs presents a quick, non-invasive way to obtain real-time information about the cancer disease status. In combination with other diagnostic methods, doctors may be able to design specific responses to fight the diagnosed cancer.

Combining this insight with the ability to match drugs according to disease mutation and resistance, isolating wholly intact CTCs are the potential gold standard for the detection of cancer metastasis.

All from a simple blood draw

How We Help

With Clearbridge BioMedics' ClearCell® FX system, oncologists and researchers have a faster, more elegant solution for cell enrichment.

Fully automated and entirely label-free, the ClearCell® FX system empowers doctors through every step of the cancer treatment journey.

Based on the patented microfluidic biochip, CTChip®FR1, the ClearCell® FX system achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring.

Clinicians now have a robust and reproducible non-invasive liquid biopsy to monitor metastasis - bringing us closer to providing timely, tailored treatment for patients.

Researchers will also have a highly sensitive assay for CTC enrichment with a larger dynamic range which enables deeper insights and greater understanding of tumour biology.

ClearCell® FX System
Label-free CTC Enrichment for Real-time Insights
How It Works
ClearCell® FX System
Driven by CTChip®FR1

The ClearCell® FX System, driven by the ClearCell® CTChip®FR1, is one of the world's first fully automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in under an hour.

Combined with the high levels of purity, the CTCs are enriched in suspension, that allows for easy integration with downstream molecular analyses and diagnostic assays. Meaning that researchers and clinicians can use these insights to provide timely, tailored treatment options.

How it works:
The CTChip® FR1

The microfluidic biochip captures CTCs based on inertial characteristics such as size and deformity, relative to other blood components, by using Dean Flow Fractionation (DFF). Through the DFF process, the cells are focused within the microfluidic channels of the CTChip® FR1, with larger cells along the inner wall and the smaller cells away from it. This label-free approach ensures effective, continuous and quick separation while retaining cell viability thus lending itself to a myriad of downstream applications.

How it works:
The CTChip® FR1
How It Works
Application Notes
Product Information
Sales Materials
Application Notes
Fluorescence In Situ Hybridisation (FISH)
EML4-ALK gene rearrangement in a non-small cell lung cancer (NSCLC) CTC that had been isolated with the ClearCell® FX System and analysed by FISH. Image courtesy of National Cancer Centre, Singapore
Cell Culture
MCF7 breast cancer cells in culture after isolation using the CTChip® FR1
Molecular Analysis
Detection of a KRAS mutation in a CTC- enriched sample that had been isolated using the ClearCell® FX System and analysed by Sanger sequencing
Immunofluorescence (IF) / Immunocytochemistry (ICC)
DAPI (in blue), pan-cytokeratin (CK) (in green) and EpCAM (in red) staining of cells isolated using the ClearCell® FX System. CTCs are shown to be CK + and EpCAM
Need more information and can't find it? Drop us a note at contactus@clearbridgebiomedics.com
Product Information
For reference only, please contact your country distributor or Clearbridge BioMedics for any updated versions if applicable.
Sales Materials
For reference only, please contact your country distributor or Clearbridge BioMedics for any updated versions if applicable.
For reference only, please contact your country distributor or Clearbridge BioMedics for any updated versions if applicable.

[under construction]

Top UK poster presentation award for NUS Engineering student on the CTChip®
Clearbridge BioMedics' Founder wins prestigious President's Technology Award 2011, Singapore
News Feature: Clearbridge BioMedics Founders interviewed in The Straits Times Money section
Upcoming Events in 2016
AMP 2016 Annual Meeting
November 10-12 2016
(Charlotte, North Carolina)
Booth #2004
NCRI Cancer Conference 2016
November 6-9 2016
(Liverpool, UK)
Booth #82
ASCO Annual Meeting 2016
June 3-7 2016 (Chicago, Illinois)
Booth #17085
AACR Annual Meeting 2016
April 16, 2016 to April 20, 2016
(New Orleans, Louisiana)
Exhibitor | Booth number #5039
Poster presentations
» Abstract #2243
» Abstract #3953
» Abstract #5008
ASCO Annual Meeting 2015
May 30, 2015 to June 1, 2015
(Chicago, Illinois)
Exhibitor | Booth number #5039
AACR Annual Meeting 2015
April 18, 2015 to April 22, 2015
(Philadelphia, Pennsylvania)
Exhibitor | Booth number #1955
The Multidisciplinary Lung Cancer Conference 2015
March 27, 2015 to March 29, 2015
Molecular Med Tri-Con 2015
February 15, 2015 to February 20, 2015
(San Francisco, California)
Please check back for more details.
ClearCell® FX System
About Us
About Clearbridge BioMedics

Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government's National Research Foundation (NRF).

The ClearCell FX System by Clearbridge BioMedics provide a label-free means of Circulating Tumour Cell (CTC) enrichment that offers a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive "liquid biopsy" approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.


Our Mission

Clearbridge BioMedics' mission is to innovate and develop novel medical research tools and diagnostic products using cutting-edge technologies, in order to catalyse medical research and discovery, revolutionise disease management, and advance patient care.



Clearbridge BioMedics believes in bringing clarity to cancer, providing each and every patient with timely, tailored treatment.

Board of Directors
Johnson CHEN
Chairman and Founder

Mr Chen is the Managing Partner for Clearbridge Partners, an Asian venture capital firm. He is also the Managing Partner for Clearbridge Accelerator, a Singapore National Research Foundation (NRF) backed high-technology incubator and an investment committee member of Clearbridge BSA Pte Ltd... [+]

Chee Wah CHONG
Director and Founder

Mr Chong previously worked as a Communications Security Program Manager at the DSO National Laboratories. He won the prestigious KINETIC Award in DSO for his outstanding technical contributions to various initiatives in the defence sector... [+]


Mr Qian was the vice president, the director of public affairs and the secretary of the Board of Trauson Holdings Company Limited. Mr. Qian graduated from Simon Fraser University in Canada with both BBA and MBA degrees. He is now a registered senior economist... [+]

Joo Hock CHUA

Mr Chua joined the former Singapore Technologies Group in 1987 where he was involved in the early phase of Singapore Technologies' venture capital investments which became Vertex in 1988... [+]

Juanita FU, MD

Dr. Juanita Fu is a General Partner of Bioveda Capital, a venture capital firm focused exclusively on investments in healthcare and biotechnology. She has more than ten years of clinical experience with a focus on internal medicine... [+]

Nicolas H. Roelofs, PhD

Dr Nicolas H. Roelofs served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group from 2009 to 2013. He also served as the Vice President and General Manager of the Life Sciences division from 2006 to 2009... [+]

Prof. LIM Chwee Teck
Advisor and Founder

Professor Lim Chwee Teck currently holds joint appointments at both the Departments of Bioengineering and Mechanical Engineering at the National University of Singapore (NUS). He is also a Principal Investigator at the Mechanobiology Institute... [+]

TAN Swee Jin, PhD
Technical Advisor and Founder

Dr Tan is one of the rising stars in the field of nanobiomechanics. He is the co-inventor for the Circulating Tumour Cell (CTC) Microfiltration BioChip - an innovative device which allows clinicians to isolate and enumerate circulating tumour cells... [+]

Management Team
Michael Paumen, PhD
Chief Executive Officer

Dr Michael Paumen, CEO of Clearbridge BioMedics held several senior leadership positions in the biotech and biomedical industries prior to joining the Company. Previously, Dr Paumen was with Life Technologies...[+]

Andrew WU, PhD
Chief Operating Officer

Dr Wu is currently serving as Chief Operating Officer of Clearbridge BioMedics, overseeing the company's business, product and research development and general operations which include regulatory approvals... [+]

Ali Asgar BHAGAT, PhD
Senior Technical Director

Dr Ali Asgar Bhagat received his M.S. (2006) and Ph.D. (2009) in Electrical Engineering from the University of Cincinnati, USA... [+]

Junquan HUANG
Director, Product Development

Junquan leads design translation
and product commercialisation for Clearbridge BioMedics. He directs product design, engineering and software development initiatives to meet both commercially-ready products and international regulatory standards, relevant to clinicians and pathology laboratories dedicated to cancer diagnostics... [+]


The Chadwick, 81 Science Park Drive, #02-03, Singapore 118257
+65 6873 0668
+65 6873 0778
Contact Us
Interested to be an early access partner or distributor of our products? We want to hear from you.
Antispam Question Total of 10+8 =

By submitting this form, I agree to be contacted by Clearbridge BioMedics Pte Ltd
for present and future purposes specific to cancer management, CTCs and
Clearbridge BioMedics' range of products and services.

© All Rights Reserved Clearbridge Biomedics 2014
Disclaimer: Clearbridge BioMedics Pte Ltd's range of ClearCell® Systems are for Research Use Only (RUO), and not intended for human diagnostic use. ClearCell® and CTChip® are registered trademarks of Clearbridge BioMedics Pte Ltd. All warranties, both expressed and implied, with respect to the product, including but not limited to, any implied warranty of merchant ability or fitness for a particular purpose, and all such representations are hereby excluded to the fullest extent permitted by law. Clearbridge BioMedics Pte Ltd and its affiliates shall not be liable for any direct, indirect, incidental or consequential damages caused by the product. No person has any authority to bind the Company or its affiliates to any representation or warranty with respect to the product. If any part or term of this disclaimer is held to be illegal, unenforceable or in conflict with applicable law by a court of competent jurisdiction, the validity of the remaining portions of this disclaimer shall not be affected, and all rights and obligations shall be construed and enforced as if this disclaimer did not contain the particular part or term held to be invalid. Please contact the Company for more information.